metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Update on osteo-articular infections and severe skin and soft tissue infections
Información de la revista
Vol. 25. Núm. S1.
Programa de control externo de calidad SEIMC. Año 2006
Páginas 28-36 (enero 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 25. Núm. S1.
Programa de control externo de calidad SEIMC. Año 2006
Páginas 28-36 (enero 2007)
“Update on infectious diseases”
Acceso a texto completo
Update on osteo-articular infections and severe skin and soft tissue infections
Actualización de las infecciones osteoarticulares y las infecciones graves cutáneas y de los tejidos blandos
Visitas
1291
José Barberána,
Autor para correspondencia
josebarberan@teleline.es

Correspondence: Dr. J. Barberán. Hospital de la Defensa Gómez Ulla. Grta. Ejército, s/n. 28047 Madrid. Spain.
, Alex Sorianob, Álvaro Pascualc, Javier Cobod, Javier Arizae, Xavier Floresf, Antonio Guerrerog, José Hernández-Queroh, Cristina Fernándezi, José Corderoj, José Ramón Azanzak
a Infectious Diseases Service. Hospital de la Defensa Gómez Ulla. Madrid. Spain
b Infectious Diseases Service. Hospital Clínic. Barcelona. Spain
c Department of Microbiology. School of Medicine. Sevilla. Spain
d Infectious Diseases Service. Hospital Ramón y Cajal. Madrid. Spain
e Infectious Diseases Service. Hospital de Bellvitge. Hospitalet del Llobregat. Barcelona. Spain
f Septic Unit of Orthopedic Surgery and Traumatology Department. Hospital Universitario Vall d’Hebron. Barcelona. Spain
g Biological Diagnosis. Hospital de la Ribera. Valencia. Spain
h Infectious Diseases Unit. Hospital Clínico San Cecilio. Granada. Spain
i Clinical Epidemiology Unit. Hospital Clínico San Carlos. Madrid. Spain
j Orthopedic Surgery and Traumatology Unit. Hospital Universitario de la Princesa. Madrid. Spain
k Infectious Diseases Department. Clínica Universitaria. Pamplona. Navarra. Spain
Ver más
Este artículo ha recibido
Información del artículo

The present article is an update on bone, joint, skin and soft-tissue infections. A panel of Spanish clinicians including orthopedic surgeons, infectious diseases specialists and microbiologists with extensive experience in these fields have commented on the most relevant medical articles published during the last two years.

In the next section, we review and discuss 10 articles on pathogenesis (1), diagnostic methods (1), epidemiology (1) and general management of prosthetic joint infections (8) and three on severe and necrotizing soft tissue infections. Although the rate of joint arthroplasty infection is about 1-3%, the infection of an orthopedic implant is particularly devastating since it requires several interventions, prolonged hospitalization and antibiotic treatment for weeks or months. Taking into account the increasing number of arthroplasties performed each year, a parallel increase is expected in the number of prosthetic joint infections. In the absence of well-designed prospective, randomized, controlled studies, the diagnosis and treatment of prosthetic joint infections is based mainly on personal experience. For these reasons, the authors consider particularly interesting a critical review of the most important references in this field.

Recently, emergent pathogens such as community-acquired methicillin-resistant Staphylococcus aureus have been involved in necrotizing fasciitis. In addition, new tools for the diagnosis and treatment of these infections have been described and are now reviewed in the present article.

Key words:
Osteomyelitis
Prosthetic joint infection
Necrotizing fascitis
Community-acquired infections
Staphylococcus aureus

El artículo presente recoge una actualización de las infecciones óseas, articulares, cutáneas y de los tejidos blandos. Un grupo de clínicos españoles constituido por traumatólogos, especialistas en enfermedades infecciosas y microbiólogos con amplia experiencia en estos campos ha comentado los artículos de mayor relevancia a este respecto publicados durante los 2 últimos años.

En la sección siguiente se revisan y comentan 10 artículos sobre patogenia (1), métodos diagnósticos (1), epidemiología (1) y abordaje terapéutico general de las infecciones en las prótesis articulares (8); además, se exponen los resultados obtenidos en tres publicaciones sobre infecciones necrosantes graves de los tejidos blandos. A pesar de que la incidencia de infección de las artroplastias es de aproximadamente el 1-3%, la infección de un implante ortopédico es un cuadro especialmente grave debido a que obliga a la realización de varias intervenciones quirúrgicas, a una hospitalización prolongada y a la administración de tratamiento antibiótico durante semanas o meses. Considerando en conjunto el número creciente de intervenciones de artroplastias que se realizan anualmente, se espera un incremento paralelo en el número de infecciones de las prótesis articulares. En ausencia de estudios prospectivos y realizados con asignación aleatoria y control, el diagnóstico y el tratamiento de las infecciones de las prótesis articulares están fundamentados principalmente en la experiencia personal. Por estas razones, los autores consideran especialmente interesante una revisión crítica de las publicaciones más importantes que se han efectuado en este campo.

Recientemente se han observado cuadros de fascitis necrosante de origen extrahospitalario causados por Staphylococcus aureus resistente a meticilina.

Además, en el artículo presente se revisan las nuevas herramientas introducidas para el diagnóstico y el tratamiento de estas infecciones.

Palabras clave:
Osteomielitis
Infección de prótesis articulares
Fascitis necrosante
Infecciones extrahospitalarias
Staphylococcus aureus
El Texto completo está disponible en PDF
References
[1.]
D.P. Lew, F.A. Waldvogel.
Osteomyelitis.
[2.]
J. LeFrock, A. Ristuccia.
Teicoplanin in the treatment of bone and joint infections: An open study.
J Infect Chemother, 5 (1999), pp. 32-39
[3.]
C.R. Rayner, L.M. Baddour, M.C. Birmingham, C. Norden, A.K. Meagher, J.J. Schentag.
Linezolid in the treatment of osteomyelitis: results of compassionate use experience.
Infection, 32 (2004), pp. 8-14
[4.]
R.M. Donlan.
Biofilm formation: a clinically relevant microbiological process.
Clin Infect Dis, 33 (2001), pp. 1387-1392
[5.]
M.J. Spangehl, B.A. Masri, J.X. O’Connell, C.P. Duncan.
Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties.
J Bone Joint Surg Am, 81 (1999), pp. 672-683
[6.]
B.D. Mariani, R.S. Tuan.
Advances in the diagnosis of infection in prosthetic joint implants.
Mol Med Today, 4 (1998), pp. 207-213
[7.]
W. Zimmerli, A. Trampuz, P.E. Ochsner.
Prosthetic-joint infections.
N Engl J Med, (2004), pp. 3511645-3511654
[8.]
L. Bernard, P. Hoffmeyer, M. Assal, P. Vaudaux, J. Schrenzel, D. Lew.
Trends in the treatment of orthopaedic prosthetic infections.
J Antimicrob Chemother, 53 (2004), pp. 127-129
[9.]
M. Bassetti, F. Vitale, G. Melica, E. Righi, A. Di Biagio, L. Molfetta, et al.
Linezolid in the treatment of Gram-positive prosthetic joint infections.
J Antimicrob Chemother, 55 (2005), pp. 387-390
[10.]
M.D. Kalmeijer, E. Nieuwland-Bollen, D. Bogaers-Hofman, G.A. de Baere.
Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery.
Infect Control Hosp Epidemiol, 21 (2000), pp. 319-323
[11.]
D.L. Stevens, A.L. Bisno, H.F. Chambers, E.D. Everett, P. Dellinger, E.J. Goldstein, et al.
Practice guidelines for the diagnosis and management of skin and soft-tissue infections.
Clin Infect Dis, 41 (2005), pp. 1373-1406
[12.]
E.A. Eady, J.H. Cove.
Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus-an emerging problem for the management of skin and soft tissue infections.
Curr Opin Infect Dis, 16 (2003), pp. 103-124
[13.]
J.N. Sharpe, E.H. Shively, H.C. Polk Jr.
Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
Am J Surg, 189 (2005), pp. 425-428
[14.]
R.D. Arbeit, D. Maki, F.P. Tally, E. Campanaro, B.I. Eisenstein.
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
Clin Infect Dis, 38 (2004), pp. 1673-1681
[15.]
M.E. Stryjewski, W.D. O’Riordan, W.K. Lau, F.D. Pien, L.M. Dunbar, M. Vallee, et al.
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Clin Infect Dis, 40 (2005), pp. 1601-1607
[16.]
L.E. Jauregui, S. Babazadeh, E. Seltzer, L. Goldberg, D. Krievins, M. Frederick, et al.
Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
Clin Infect Dis, 41 (2005), pp. 1407-1415
[17.]
E.J. Ellis-Grosse, T. Babinchak, N. Dartois, G. Rose, E. Loh.
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
Clin Infect Dis, 41 (2005), pp. S341-S353
[18.]
A.F. Widmer, R. Frei, Z. Rajacic, W. Zimmerli.
Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections.
J Infect Dis, 162 (1990), pp. 96-102
[19.]
A.J. Mangram, T.C. Horan, M.L. Pearson, L.C. Silver, W.R. Jarvis.
Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee.
Am J Infect Control, 27 (1999), pp. 97-132
[20.]
W. Zimmerli, A.F. Widmer, M. Blatter, R. Frei, P.E. Ochsner.
Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group [see comments].
JAMA, 279 (1998), pp. 1537-1541
[21.]
A. Soriano, S. Garcia, M. Ortega, M. Almela, X. Gallart, J. Vila, et al.
Treatment of acute infection of total or partial hip arthroplasty with debridement and oral chemotherapy.
Med Clin (Barc), 121 (2003), pp. 81-85
[22.]
A.M. Lovering, J. Zhang, G.C. Bannister, B.J. Lankester, J.H. Brown, G. Narendra, et al.
Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement.
J Antimicrob Chemother, 50 (2002), pp. 73-77
[23.]
M. Bassetti, A. Di Biagio, G. Cenderello, B.V. Del, A. Palermo, M. Cruciani, et al.
Linezolid treatment of prosthetic hip Infections due to methicillin-resistant Staphylococcus aureus (MRSA).
J Infect, 43 (2001), pp. 148-149
[24.]
I. Mogenet, S. Raetz-Dillon, J.M. Canonge, M. Archambaud, E. Bonnet.
Successful treatment of Staphylococcus epidermidis hip prosthesis infection with oral linezolid.
Ann Pharmacother, 38 (2004), pp. 986-988
[25.]
A. Jover-Saenz, F.B. Gaite, A.G. Ribelles, J.M. Porcel-Pérez, S. Garrido-Calvo.
Linezolid treatment of total prosthetic knee infection due to methicillin-resistant Staphylococcus epidermidis.
J Infect, 47 (2003), pp. 87-88
[26.]
G.M. Vincent, J.D. Amirault.
Septic arthritis in the elderly.
Clin Orthop Relat Res, (1990), pp. 241-245
[27.]
C.H. Wong, H.C. Chang, S. Pasupathy, L.W. Khin, J.L. Tan, C.O. Low.
Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality.
J Bone Joint Surg Am, 85-A (2003), pp. 1454-1460
[28.]
S.K. Fridkin, J.C. Hageman, M. Morrison, L.T. Sanza, K. Como-Sabetti, J.A. Jernigan, et al.
Methicillin-Resistant Staphylococcus aureus Disease in Three Communities.
N Engl J Med, 352 (2005), pp. 1436-1444
[29.]
R. Kaul, A. Mcgeer, A. Norrby-Teglund, M. Kotb, B. Schwartz, K. O’Rourke, et al.
Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome-a comparative observational study. The Canadian Streptococcal Study Group.
Clin Infect Dis, 28 (1999), pp. 800-807
Copyright © 2007. Elsevier España S.L.. All rights reserved
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos